Viz.ai Launches New Strategic Alliance to Accelerate Timely Diagnosis and Deliver AI-Powered Precision Care for Patients with Cancer

Viz.ai Launches New Strategic Alliance to Accelerate Timely Diagnosis and Deliver AI-Powered Precision Care for Patients with Cancer

SAN FRANCISCO--(BUSINESS WIRE)--Jun 2, 2025-

AI Can Help Patients Get Prostate Cancer Drug That Cuts Death Risk By Half

The new AI test, built by a team from the US, UK and Switzerland, shows which men would most likely benefit from abiraterone.

AI in Public Health: Revolution, Risk and Opportunity - Medika Life

AI is reshaping health, enhancing disease surveillance and diagnostics, and easing workforce burdens — but it also raises complex risks and ethical questions.

Isotopia and Cardirad Announce Launch of Isoprotrace® in Sweden and Denmark, Expanding Access to Advanced Prostate Cancer Imaging ⋆ TOP News Österreich - Nachrichten aus Österreich und der ganzen Welt

Isotopia Molecular Imaging, in partnership with Cardirad , proudly announces the launch of Isoprotrace®—an advanced Gallium-68 Gozetotide preparation kit for prostate cancer imaging—in Sweden and Denmark. The introduction of Isoprotrace® into these Nordic markets marks a significant step forward in expanding access to precision diagnostic tools for prostate cancer. Isoprotrace® is a ready-to-use, multi-dose kit designed for the efficient prepar…

New AI Tools Predict Which Men Will Respond to Prostate Cancer Treatments

Medical professionals have created an artificial intelligence tool capable of predicting which men diagnosed with prostate cancer are likely to benefit from treatment, potentially lowering the risk of mortality. Abiraterone is regarded as a revolutionary treatment for the condition, which is the most prevalent cancer among men in over 100 countries. It has already enabled [...] Source The post New AI Tools Predict Which Men Will Respond to Prost…

AI Breakthrough Personalizes Prostate Cancer Treatment

In a significant advancement for prostate cancer care, researchers from the US, UK, and Switzerland have developed an artificial intelligence (AI) tool capable of predicting which men with high-risk, non-metastatic prostate cancer will benefit from the drug abiraterone. This development, unveiled at the American Society of Clinical Oncology’s annual meeting, promises to tailor treatment plans more effectively, potentially improving outcomes and …